Several members of the Wnt gene family have been shown to cause mammary tumors in mouse. Using degenerate primer polymerase chain reaction (PCR) on human genomic DNA, and speci®c PCR of cDNA libraries, we have isolated a WNT gene which has not previously been described in human. The gene is the human homologue of mouse Wnt10b, recently shown to be one of the oncogenes cooperating with FGF3 in the development of mouse mammary tumour virus (MMTV) induced mouse mammary carcinomas. The human WNT10B sequence was 88% and 95% identical to the murine gene at nucleotide and amino acid levels, respectively. YAC FISH mapping localises the gene to 12q13, a chromosomal region frequently rearranged in human tumours and also containing the WNT1 gene. In normal and benign proliferations of human breast tissue, WNT10B expression was not detected by ribonuclease protection assays but was found at low levels in RT ± PCR experiments. In contrast, using both methods, WNT10B expression was found to be elevated in 3 of 50 primary breast carcinomas. Southern blot analysis of the carcinoma expressing the highest levels of WNT10B showed no ampli®cation or rearrangement of the gene. The WNT10B gene was also expressed in some cancer and non cancerous breast cell lines. These ®ndings suggest that the WNT10B gene may be involved in human breast cancer, and show that there is dierential expression of the WNT10B gene in benign and malignant disease.
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The Wnt genes are a family of highly conserved genes, present in species ranging from invertebrates to mammals, which have a role in the morphological development of tissues in both embryonic and adult contexts (Nusse and Varmus, 1992; McMahon, 1992) . Previous studies have suggested a role for Wnt genes in mammary tissue biology (Gavin and McMahon, 1992; Buhler et al., 1994; Edwards et al., 1992; Lin et al., 1992) . In the mouse, a subset of Wnt genes are involved in the development of the mammary gland and aberrant expression of those Wnt genes normally silent or expressed at low levels in this tissue causes mammary carcinomas. Thus mouse Wnt1, Wnt3, and recently Wnt10b, has been shown to be some of the oncogenes insertionally activated in the process of MMTV induced carcinogenesis (Nusse and Varmus, 1982; Roelink et al., 1990; Lee et al., 1995) . Furthermore, murine Wnt1, Wnt2, Wnt3a, Wnt5b, Wnt7a and Wnt7b but not Wnt4, Wnt5a and Wnt6 have been shown to transform mouse epithelial cells in vitro (Wong et al., 1994) .
To date the known members of the Wnt family in humans are WNT1, WNT2, WNT3, WNT3A, WNT4, WNT5A, WNT7A, WNT7B and WNT8B (van Ooyen et al., 1985; Wainwright et al., 1988; Roelink et al., 1993; Huguet et al., 1994; Clark et al., 1993; Lejeune et al., 1995; Lako et al., 1996) . In studying the role of Wnt genes in human breast biology, we have previously shown that WNT2, WNT3, WNT4, WNT5A and WNT7B genes are expressed in normal human tissue and that elevated levels of WNT2, WNT5A and WNT7B genes are found in proliferative lesions of the breast (Huguet et al., 1994; Lejeune et al., 1995) . Although these studies have established the expression pro®les of several WNT genes in breast tissue, human homologues of a number of Wnt genes in lower organisms have not yet been isolated, and therefore their possible role in breast biology has not been investigated.
Here we described the cloning and characterisation of a novel human WNT gene (WNT10B). We mapped WNT10B gene to chromosome 12q13 and analysed its expression in normal human breast tissues, benign breast proliferations and breast carcinomas. (Gavin et al., 1990) , were used to amplify a 420 bp band from human genomic DNA. The PCR conditions were: 1 cycle of 948C for 4 min, 35 cycles of 948C for 1 min, 608C for 2 min and 728C for 3 min, and followed by 1 cycle of 728C for 10 min. The PCR product was cloned into pCR vector (Invitrogen) and colonies which did not hybridise to known human WNT probes were further sequenced using an ABI automated sequencer. One novel clone (G81) had a sequence that exhibited 94.5% identity over 130 amino acids to the published mouse Wnt10b sequence (Lee et al., 1995) (also called Wnt12 by Adamson et al., 1994) and was therefore named human WNT10B.
Since WNT10B cDNA was present at low abundance in the cDNA libraries tested (data not shown), a PCRbased strategy was adopted. Speci®c primers M5'10bF (5'-CCAACACCGTGTGCTTGACC-3') (Lee et al., 1995) and H10BR (5'-GGCTGCCACAGCCATC-CAAC-3') were used to amplify a 910 bp partial WNT10B cDNA clone from a 17-week human fetal brain cDNA library in Lambda ZapII (Stratagene) using the PCR conditions as described above. The sequence of this clone (10BLI2) was found to be 96% identical to mouse Wnt10b over 303 amino acids and contained the expected conserved cysteine residues and glycosylation sites (Figure 1 ). The sequence corresponded to nucleotides 461 to 1371 of the mouse Wnt10b cDNA, where the coding sequence extended from nucleotides 331 to 1500 (Lee et al., 1995) . In parallel to these experiments, a clone was identi®ed in the sequence analysis project of Human Genome Sciences Inc. in a human fetal brain cDNA library (donated by Dr Bento Soares, Columbia University, USA). This clone (designated HIBCC37) contained 841 bp of the 3' coding sequence and an additional 146 bp of 3' untranslated sequence. PCR of a vectorette library constructed from ICI YAC clone 28AD4 using the universal vectorette primer and H10BR2 (5'-GGTCAAGCACACGGTGTTGG-3') chosen from the 5' end of the 910 bp cDNA clone generated another 281 bp of the most 5' region and completed the coding sequence of human WNT10B (Figure 1) . The sequence of WNT10B shows the typical conservation of cysteine residues and N-linked glycosylation site common to all Wnt genes. A number of non cysteine residues which are either absolutely or frequently conserved amongst the Wnt genes are also present (Figure 1 ). The human WNT10B gene is 95% identical to the mouse Wnt10b gene over 389 amino acids. Chromosomal assignment of the human WNT10B gene PCR screening of a human/hamster or mouse monochromosomal somatic cell hybrid panel (UK HGMP Resource Centre) was used to amplify a 204 bp fragment from exon 4 of the WNT10B gene using human speci®c primer H10BF (5'-TGGGCCGGGCCATCTTATT-3') and primer H10BR under the same PCR conditions described above. The WNT10B gene was found to be located on chromsome 12 (data not shown). The same PCR approach was used to screen the ICI YAC library (UK HGMP Resource Centre) using conventional methods (Anand et al., 1990) . Two positive YAC clones were identi®ed (26BB4, 28AD4) to contain the WNT10B gene and used in the¯uorescence in situ hybridisation (FISH) to metaphase spreads as described (Fantes et al., 1992) . Both YACs were non chimaeric and mapped to chromosome 12q13 (Figure 2 ). In mouse, the Wnt10b and Wnt1 genes mapped to within 2.3 cM of each other on chromosome 15 (Adamson et al., 1994) , a region syntenic with human chromosome 12q13 (Mock et al., 1994) which also contained the human WNT1 gene. In addition, one of the YACs identi®ed (28AD4) also gave positive PCR signals with primers speci®c for both WNT1 and WNT10B (data not shown). This conservation of synteny along with high sequence identity con®rmed that the WNT10B gene presented is indeed the orthologue of mouse Wnt10b. The chromosomal localisation of WNT10B is of interest from the point of view of tumorigenesis such as chromosomal rearrangements involving 12q13-q15 were frequently observed in various soft tissue tumours (Nilbert et al., 1995; van den Ven et al., 1995) , and 12q13 was a common site for human papilloma virus integration in cervical carcinoma (Lazo et al., 1992) .
Analysis of WNT10B expression in human breast cell lines and tissues
Recently, mouse Wnt10b was identi®ed at a MMTV insertion site in mouse mammary tumours (Lee et al., 1995) . In addition, it was found to be expressed in virginal mouse breast tissue and when insertionally activated by MMTV, could cooperate with FGF3 to cause mouse mammary cancers (Lee et al., 1995) . Table  1 shows the expression of WNT10B in a panel of human breast cell lines as detected using the ribonuclease protection analysis. WNT10B expression was variable with, on average, 10 mg of RNA producing detectable signals after 48 h exposure. WNT10B expression was higher in cell lines from invasive breast cancer with the exception of HB2. Amongst the breast cancer cell lines, no relationship could be observed between hormone receptor status and level of WNT10B expression. WNT10B was not detected in the MCF-7 parental breast cancer cell line (MCF-7 wt), but was expressed in a multidrug resistant clone which has lost estrogen receptor expression and is able to grow in a hormone independent manner in vitro and in vivo (MCF-7 Adr r ). The variability between cell lines may provide a model system both for transfection of WNT10B and antisense experiments to further evaluate the role of human WNT10B in breast cancer.
Expression of WNT10B was also examined in normal breast tissues, benign breast lesions and primary breast carcinomas. Of these, this assay only detected expression in three out of 50 carcinomas tested (Figure 3) . The elevated level of WNT10B expression in three out of 50 human primary breast carcinomas is consistent with the hypothesis that WNT10B may contribute to the transformed phenotype in a minority of breast cancers. The WNT10B expression was further examined by RT ± PCR followed by Southern hybridisation. This technique con®rmed the higher levels of WNT10B expression in the three carcinomas above, and showed that lower levels of expression of WNT10B were present in all other samples tested (Figure 4) . Two of the three carcinomas expressing higher levels of WNT10B (cases 22 and 24) were large, locally invasive and lymph node positive tumours. Of these, one (case 22) was estrogen receptor positive and epidermal growth factor receptor negative, whilst the other (case 24) was estrogen receptor negative and epidermal growth factor receptor positive. The third carcinoma with a high level of WNT10B expression (case 9) was a small, lymph node negative, estrogen receptor negative and epidermal growth factor receptor negative tumour. Therefore, two of the three cases with elevated levels of WNT10B showed some common clinical features in that they presented with large and locally invasive carcinomas.
Southern blot analysis was performed to investigate the possibility of genomic ampli®cation or rearrangement of WNT10B in the over-expressing carcinomas. 10 mg of genomic DNA was digested with EcoRI, HindIII or SalI, electrophoresed on 0.7% agarose gels, blotted onto Hybond-N+ membranes (Amersham) and hybridised to a 32 P-labeled 1.2 kb PstI WNT10B cDNA fragment from HIBCC37. No evidence of ampli®cation or rearrangement of the gene could be found (data not shown). Therefore, the increased expression of WNT10B in these cancers is presumably related to increased transcription or increased mRNA stability.
In summary we report the isolation and chromosomal mapping of a novel WNT gene previously undescribed in the human. The expression of this gene in human breast tissue further strengthens the data suggesting a role for WNT genes in human breast biology, and its upregulation parallels recent results in mouse experimental models of breast cancer. MCF-7 Adr r SKBr3 MDA-MB-435 MDA-MB-157 a Figure 3 (a) Ribonuclease protection analysis of WNT10B mRNA expression in human breast tissues. 10 mg of total cellular RNA was used and performed as described in Table 1 . Signals are shown for WNT10B and GAPDH protected fragments after 7 days and 1 day exposure, respectively. Lanes 1 ± 24 represent RNA extract from primary breast cancers, lanes 25 ± 27: RNA from benign breast tissues, and lane 28: (b) RNA from HB2 cells. Carcinomas 9, 22 and 24 expressed elevated levels of WNT10B -872 -603 -310 -234 -194 -118 bp 1 2 3 4 5 6 7 8 9 10 11 12 13 v v Figure 4 Southern blot analysis of reverse transcriptase PCR in human breast samples. Reverse transcription was performed at 378C using Moloney murine reverse transcriptase (GIBCO-BRL) with primer P2. The resulting single stranded cDNA was ampli®ed using primers P1 and P2 to yield a 309 bp PCR product which was then electrophoresed, blotted onto Hybond-N+ membranes (Amersham) and hybridised to 1.2 kb PstI fragment of WNT10B cDNA from HIBCC33. Autoradiography was done at 7708C for 12 h with intensifying screens. Lane 1: HB 2 cells; lane 2: placenta; lanes 3, 4, 7, 9 and 11: primary breast carcinomas: lanes 5, 6 and 13: normal breast tissue; lanes 8, 10 and 12: benign breast disease. Carcinomas 22 and 24 in Figure 3 are highlighted
